A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of [225Ac]Ac-FL-020 in Participants With mCRPC
Latest Information Update: 12 Feb 2025
At a glance
- Drugs Actinium 225 FL 020 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; First in man
- Sponsors Full-Life Technologies
Most Recent Events
- 24 Sep 2024 Planned initiation date changed from 1 Jul 2024 to 1 Oct 2024.
- 24 Sep 2024 Status changed from not yet recruiting to recruiting.
- 09 Jul 2024 Status changed from planning to not yet recruiting.